Ruti Aga's six-year ban: a fake prescription and the price of a cover-up

On the desk of the Athletics Integrity Unit file sits a prescription. It carries the name of a medical clinic, a doctor's signature, a stamp, a date. In the case of Ruti Aga — the Ethiopian marathoner who won the 2026 Tokyo Marathon — that sheet of paper became the heaviest piece of evidence against her, heavier than the prohibited substance found in her sample.

The clinic on the form does not exist.

The person who signed it is a family member with no medical registration.

The prescription pad was taken from a facility where that person never worked — and the facility confirmed as much in writing to the AIU.

Three independent layers of verification, three collapses of the story. The outcome: a six-year ban effective 10 September, plus annulled results and forfeited prize money.

I have read through this case several times, and what stopped me was not the number six. What stopped me was the way a world-class athlete, with a support team everyone assumes is professional, chose precisely the option most likely to be caught out of all the options available.

Who she was before the prescription

Ruti Aga, 32, Ethiopian. In March 2026 she won the Tokyo Marathon, one of the six most prestigious races in professional road running. Together with three runner-up finishes at World Marathon Majors events, that record places her in the elite tier of women's marathon running for the 2026–2026 window.

That is the part of the file anyone can check in three minutes. The rest is not so easy.

In March she won a half marathon in China. The source does not disclose her time there, and I have to be blunt: without a mark, any inference about the sporting significance of that win is speculation. No comparison with a personal best, no course profile, no altitude, no conditions. Only a bare fact: a half marathon in China, a win, and then an adverse analytical finding.

But one thing I can say with confidence. Across years of watching East African athletes race the Asian road circuit, I have noticed a pattern so repetitive it becomes boring: half marathons and marathons in Chinese cities pay appearance fees, sometimes with record bonuses attached, enough to make a continental-class athlete board a plane for twenty-one kilometres. This is the underground economy of professional road running, and it is no secret to anyone in the trade.

So the March race was very likely a race for money, not a race for titles. That matters, because it explains why an athlete at the peak of her career would turn up at an event with far lighter scrutiny than a World Marathon Major.

The substance, and a classification error the press keeps making

Aga's sample tested positive for methylprednisolone.

Many reports call it a "banned steroid". That is technically wrong, and the error is not harmless academic nitpicking — it skews the entire public understanding of severity.

Methylprednisolone is a synthetic glucocorticoid, meaning a corticosteroid. It sits in WADA class S9, which is prohibited in-competition only, not out-of-competition. More importantly, it is a Specified Substance — a category the regulators acknowledge is far more plausibly linked to inadvertent or therapeutic use than other classes.

What does that mean in practice? It means the baseline sanction for a Specified Substance finding, absent proof of intent, generally stops at two years. That is the softer branch of the system. That is the branch any sports lawyer would try to steer a client into.

Aga had a story that fitted that branch. She said she had a knee injury and took medication to treat it. With a glucocorticoid, that is a pharmacologically coherent explanation — corticosteroids are widely used for joint inflammation, tendinopathy, soft-tissue injury. Had the story stopped there, and had a valid therapeutic use exemption existed, the case could have ended with a light sanction, or none at all.

The story did not stop there.

The TUE: the clause people leave blank

Within the WADA system there is a mechanism called a TUE — Therapeutic Use Exemption. An athlete with a genuine medical condition requiring a prohibited substance can apply in advance. The file contains diagnosis, indication, dosage, route of administration, timing. Approved, and the use is not a violation.

I have spent years reading scouting reports and medical files, and I have learned one thing about administrative documents: the true value of a contract lies not in the release clause, but in the clauses people hastily leave blank. One empty box in a TUE file can cost more than an entire season's prize money.

Here, there was no valid TUE. And instead of confronting that gap with an honest statement — I took medication for treatment, I did not apply, my error was procedural — the team around Aga chose to fill the gap with a piece of paper.

That decision determined the rest of her career.

Four is bigger than two: the arithmetic of a sanction

The structure of Aga's ban reads clearest when split in two: two years for the presence of a prohibited substance, and four years for tampering with evidence. The two are served consecutively, not concurrently.

This is the point most readers of the news miss. Under the WADA Code, multiple anti-doping rule violations are served back to back. Total: six years.

And here is what I consider the core finding of the whole case: the penalty for the cover-up is double the penalty for the doping. Four years against two. The system has stated very clearly what it intends to protect, and what it intends to protect is not the athlete's body — it is the integrity of the investigation.

Put differently: had Aga simply tested positive and told the truth about the knee treatment, she could have returned to racing at 34. Instead she becomes eligible again at roughly 38.

How the AIU caught a clinic that does not exist

What drew my attention most in the whole file was the verification process. It unfolded exactly as any investigative body would do it, and it moved fast enough to raise a question: why does anyone still believe forged paperwork is a strategy?

Step one: the AIU contacted the clinic named on the prescription. The clinic replied that it does not exist in that form, or did not issue the document.

Step two: the AIU checked the practitioner registration number of the signatory. There was none. The signatory was a family member.

Step three: the signatory explained that she had used an old prescription pad from a former workplace. The AIU contacted that workplace. It confirmed she had never worked there.

Three steps. None required advanced technology. All were phone calls and emails an ordinary investigator could complete in days.

This is why I tell young reporters: my shovel is data, and those measurements never lie. Here, "data" was not a performance metric. It was a registration number, a clinic name, a pad's issue date. The smallest, driest, least forgeable things.

The contrarian read: this is not really a doping story

Most commentary I have read on Aga stops at the familiar conclusion: the cover-up was worse than the crime. True, but it stops too early.

My contrarian read is this: judging by how unsophisticated the cover-up was, this is not a story about a doping system. It is a story about an empty medical support system.

Look at the details. An athlete who won Tokyo. A signatory who is a relative with no credentials. An old pad. A clinic invented from nothing. No lawyer reviewed the file before submission. Nobody in the entourage tested whether the story would survive the first phone call.

A real doping operation with money and expertise would never play this hand. It would hire a registered physician, or more simply, it would offer no explanation at all and accept two years. What Aga had was not a criminal enterprise. What she had was a vacuum — and an eager relative who filled it with the only thing he could think of.

That is why I call this an entourage failure, not a conspiracy. And this kind of failure is more common than people imagine among East African road runners.

There are gems that do not sit at the top of the leaderboard but under the dust of the bench. I wrote that years ago while following youth squads. It has a reverse side I never wrote about: athletes outside the media's coverage are also outside the coverage of legal counsel and professional medical support. When trouble arrives, they have nobody to call.

I do not look for treasure where the lights are brightest. I shine a lamp into the corners others forget. In that corner this time I found not a gem, but a trap.

What the press gets wrong, and what it costs

One small but telling detail: calling methylprednisolone an anabolic steroid inflates the perceived severity for casual readers. It erases the line between an anti-inflammatory used for injury treatment and a substance used to build muscle mass.

I am not defending anyone. Aga violated the rules and was sanctioned. But if we judge cases by feeling rather than by classification, the system loses predictability — and an unpredictable system is an unfair one.

The same applies to calling this "Ethiopia's doping case". One athlete, one family entourage, one invented clinic. There is no trace of an organised programme, no trace of federation involvement. Ethiopia has one of the deepest marathon development systems on earth, and one individual case says nothing about that system.

Every star was once a piece sitting in the wrong place on a scouting map. Conversely, a piece removed from the map does not change the map.

Ethiopia loses nothing. Aga loses everything.

This is the coldest part of the story and the least written about.

The depth of Ethiopian women's marathon running is such that removing one elite athlete from the start line barely registers in the competitive structure of the event. Kenya is the same. Both nations have a bench deep enough to absorb individual losses without a single world ranking forecast being revised.

Plainly: competitively, Aga's case changes nothing. Commercially, for her, it changes everything.

Run the revenue lines of an elite marathoner. Prize money from majors. Appearance fees from invited races. Shoe contract. Nutrition contract. And most importantly, World Marathon Majors invitations, which set the commercial value of a name.

A six-year ban from 10 September erases all of it. The Chinese half marathon result is likely annulled, dragging prize money with it. Invitations vanish. Sponsors have morality clauses ready to exit — standard practice, not exception.

And at 32, the timing lands at the peak of the earnings curve, not the decline. The pandemic summer taught me that the most buried thing is sometimes the clearest. Here, what was buried was a simple commercial fact — a marathoner earns inside a very narrow window, and that window just slammed shut at its highest point.

The Chinese circuit: a structural blind spot

One more dimension, though it reaches beyond the case file.

The violation occurred at a half marathon in China. That is not a random detail. The appearance-fee economy has concentrated large numbers of East African athletes in Asian road races with lighter testing density and simpler medical processes than European majors.

When a world-class athlete races where the organiser has no deep medical department, the only person responsible for the legality of everything in her body is herself. No team doctor. No compliance adviser. No cross-check.

That is the structural blind spot, and it is not located in Ethiopia. It sits at the intersection of money flow and scrutiny.

What remains unanswered

The source does not state the year of the March positive test, nor the year of the 10 September provisional suspension. That timeline needs verification; it is not settled fact.

The route of administration is not stated. An intra-articular injection close to competition would trigger the in-competition prohibition absent a TUE. Oral use weeks earlier would tell a different story about clearance timing.

Nor does the source say whether Aga will appeal to CAS. On the current evidentiary record — clinic denial, no registration, former employer denial — the odds of a successful appeal on length are very low.

And the source does not say whether the family member who signed faces any legal consequence. That is an open question, and an important one: if an unregistered person can sign a prescription for an international athlete without obstacle, the gap is not located in the athlete.

What I take from rereading the file

Three years of field work and one pandemic summer taught me a principle: what is most buried, if you know how to dig, becomes clearer than everything displayed on the surface. In the Aga case, what was displayed was an athlete using a banned substance. What was buried beneath was a support structure so thin it could not survive one verification call.

And this is what I think will be remembered longer than the ban itself: modern anti-doping is no longer weak at detection. It is weak at consequence management. An athlete can make a medication error — that is human, and the system has mitigation built in. But to escape that error, one must tell the truth, and to tell it in the most favourable way, one needs someone beside them who knows how to speak.

Aga had no such person.

Six years is a sentence handed down for a piece of paper. But that paper was written by a system that did not equip its athlete with the tools to defend herself with the truth. The question I leave behind, for those managing young athletes in Southeast Asia and elsewhere: when one of them is called into a testing room at two in the morning, who is the first person they think to call — and does that person know the rules?

If the answer is no, then the next prescription is being written somewhere right now.